LICENSING AGREEMENTS (Details Narrative) - USD ($)		1 Months Ended			6 Months Ended
	Dec. 12, 2020	Feb. 28, 2022	Dec. 28, 2020	May 17, 2017	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Aug. 31, 2023	Mar. 31, 2023	Sep. 30, 2021	Jan. 31, 2021	Dec. 31, 2020	Feb. 02, 2016
Number of shares													43,112
Common Stock Value					$ 1,431		$ 1,431						$ 100,000
Total obligation under the agreement	$ 100,000				$ 300,000				$ 3,000,000.0	$ 300,000	$ 300,000	$ 300,000
Initial payment of obligation	$ 50,000									$ 40,000	$ 50,000	$ 50,000
Balance of obligation, description					The remaining portion of the $300,000 obligation was paid in cash in 2020
Remaining portion of obligation								$ 100,000
Amortization expenses					$ 22,970	$ 22,970
Common Stock Shares					1,431,126		1,431,126
Carrying value of patent					$ 87,464
Amortization					0
Description of payment on conversion basis				Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date
Description for the consecutive trading days				In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles
Amortization					46,000
Initial payment				$ 100,000
Payments upon completion of the IRB clinical trial				$ 200,000
Payments in the event of commercialization of technology					300,000
Licensing Agreements [Member]
Amortization expenses					4,986	4,986
License Agreement [Member]
Amortization expenses					586	586
Carrying value of patent					1,447
Expected amount of amortization					$ 1,172
ImmCelz Patent [Member]
Common Stock, shares	667									8,466	8,929	14
Discount Rate					25.00%
Remaining portion of obligation								$ 100,000
Amortization expenses					$ 12,500	0
Interest rate					5.00%
Carrying value of patent					$ 85,000
Exercise Price					$ 0.0037
Amortization					$ 25,000
ImmCelz [Member]
Amortization expenses					12,500	12,500
Carrying value of patent					162,500
Amortization					25,000
EDI Patent [Member]
Amortization expenses					9,972
Carrying value of patent					16,055
Jadi Cell [Member]
Pyment For License fees		$ 250,000	$ 250,000
Common Stock Shares		18,018
StemSpine LLC [Member]
Amortization expenses					5,000	$ 5,000
Carrying value of patent					$ 30,000
Expiration period of finite-lived intangible assets					May 19, 2027
Amortization					$ 10,000
Option Warrant [Member]
Discount Rate				50.00%
Interest rate				5.00%
Initial payment	$ 100,000			$ 100,000
Payments upon dosing of the first patient in Phase 3 clinical trial				400,000
Payments upon dosing of the first patient first patient in a Phase 1-2 clinical trial				200,000
Option [Member]
Initial payment	$ 100,000			100,000
Payments upon signing agreement with university for the initiation of an IRB clinical trial				$ 100,000